Leap Therapeutics Raises $58.88M in Private Placement

Leap Therapeutics ( (LPTX) ) has shared an update.

On October 6, 2025, Leap Therapeutics entered into a Securities Purchase Agreement for a private placement, closing on October 8, 2025, raising approximately $58.88 million. The funds will support Leap’s new digital asset treasury strategy and ongoing therapeutic programs, including FL-501 and sirexatamab. Winklevoss Capital, the lead investor, will provide strategic support and has the right to nominate two directors to Leap’s board. The private placement was conducted under Nasdaq rules, and Parcrest acted as the placement agent.

The most recent analyst rating on (LPTX) stock is a Hold with a $1.25 price target. To see the full list of analyst forecasts on Leap Therapeutics stock, see the LPTX Stock Forecast page.

Spark’s Take on LPTX Stock

According to Spark, TipRanks’ AI Analyst, LPTX is a Underperform.

Leap Therapeutics faces significant financial challenges with persistent losses and no revenue growth, resulting in a low financial performance score. The technical analysis suggests bearish trends with some potential for short-term volatility. The company’s valuation metrics are also unfavorable due to negative earnings. No recent earnings call or corporate events data are available to impact the score further.

To see Spark’s full report on LPTX stock, click here.

More about Leap Therapeutics

Leap Therapeutics is a biotechnology company focused on developing targeted and immuno-oncology therapeutics. Its pipeline includes sirexatamab, a humanized monoclonal antibody targeting the Dickkopf-1 protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 protein.

Average Trading Volume: 3,248,511

Technical Sentiment Signal: Sell

Current Market Cap: $25.96M

For detailed information about LPTX stock, go to TipRanks’ Stock Analysis page.